Table 3. Multivariate analysis of survival.
| Hazard ratio (95% confidence interval) | P value | |
|---|---|---|
| Sex | ||
| Male | Reference | |
| Female | 0.96 (0.89–1.04) | 0.313 |
| Age | ||
| <67 | Reference | |
| >66 | 1.45 (1.35–1.56) | <0.001 |
| Marital status | ||
| Married | Reference | |
| Unmarried | 1.09 (1.01–1.17) | 0.027 |
| Race/Ethnicity | ||
| Caucasian | Reference | |
| African-American | 1.03 (0.93–1.14) | 0.580 |
| Asian | 0.78 (0.71–0.86) | <0.001 |
| Others | 0.96 (0.73–1.26) | 0.759 |
| Insurance status | ||
| Insured | Reference | |
| Uninsured | 1.08 (0.88–1.31) | 0.472 |
| Location | ||
| Cardia | Reference | |
| Fundus | 0.90 (0.73–1.10) | 0.297 |
| Body | 0.81 (0.70–0.93) | 0.002 |
| Antrum/Pylorus | 0.83 (0.75–0.91) | <0.001 |
| Lesser/greater curvature | 0.77 (0.69–0.87) | <0.001 |
| Others | 0.97 (0.87–1.09) | 0.641 |
| AJCC 6th TNM stage | ||
| I | Reference | |
| II | 2.58 (2.29–2.90) | <0.001 |
| III | 4.43 (3.96–4.95) | <0.001 |
| IV | 7.75 (6.94–8.67) | <0.001 |
| Lymph node removed | ||
| 1–3 | Reference | |
| >3 | 0.64 (0.56–0.72) | <0.001 |
| Histology subgroup | ||
| Adenocarcinoma | Reference | |
| Signet Ring cell | 1.14 (1.04–1.24) | 0.003 |
| Mucinous adenocarcinoma | 1.06 (0.87–1.30) | 0.563 |
| Grade | ||
| Well differentiated | Reference | |
| Moderately differentiated | 1.39 (1.08–1.80) | 0.012 |
| Poorly differentiated | 1.95 (1.52–2.50) | <0.001 |
| Undifferentiated | 2.18 (1.60–2.98) | <0.001 |
| Therapy (Surgery ± radiotherapy) | ||
| Therapy | Reference | |
| None | 2.06 (1.92–2.23) | <0.001 |
| Unknown | 1.51 (1.43–1.59) | <0.001 |
AJCC: American Joint Committee on Cancer.
TNM: Tumor-Node-Metastasis.